89 results about "Non covalent" patented technology

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein the first and second domains are Fab or Fc domains; wherein each of the first and second domains comprise a first polypeptide chain comprising a first N-terminus of the domain, and a second polypeptide chain comprising a second N-terminus of the domain; wherein the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage, which can be a covalent linkage or a non-covalent linkage between first and second dimerizing polypeptides attached to the first N-termini of the first and second domains, respectively; and wherein the third and fourth domains are attached at their respective C-termini to the second N-termini of the first and second domains, respectively, or the N-termini of the first and second dimerizing polypeptides.

The invention is applicable to the technical field of polymer biomedical hydrogel materials, and provides a preparation method and application of multifunctional agarose-based particle composite hydrogel based on liquid-liquid phase separation, and the agarose-based particle composite hydrogel is a product formed by introducing microsphere particles into an agarose hydrogel body matrix; the microsphere particles are formed by a prepolymer and sodium lignin sulfonate through phase separation mediated by a composite behavior based on non-covalent interaction; the prepolymer is obtained by carrying out amine-epoxy reaction on an amino compound and an epoxy compound in water. According to the prepared agarose-based particle composite hydrogel, a microsphere particle structure is formed on the surface of an agarose matrix while positively charged amino groups and sodium lignin sulfonate are introduced, so that the multifunctional agarose-based particle composite hydrogel is prepared.

This invention discloses an AfBPP-based active molecular probe for thiostreptin, its preparation, and its application, belonging to the field of chemical biology. This invention introduces a bifunctional tag integrating a photocrosslinking group (bisacrididine) and a bioorthogonal reactive group (alkynyl group) into the structure of thiostreptin. While retaining the original biological activity of the parent compound, it endows the probe with highly efficient probe function, solving the technical problem of target loss during washing and purification of traditional non-covalent probes. After target labeling, the probe can specifically connect to reporter groups such as fluorescein or biotin through click-chemical reactions, achieving efficient enrichment of drug targets. Combined with mass spectrometry analysis, it enables global identification of potential targets in cells or complex biological samples at the omics level, such as chemical proteomics, providing a powerful molecular tool for in-depth revelation of the potential targets and pharmacological mechanisms of thiostreptin.

The application relates to a fusion protein and application thereof in the field of biotechnology. A polypeptide fragment for specifically recognizing a single-molecule phospholipid membrane and a polypeptide fragment for specifically recognizing a tissue or a cell are connected to form a fusion protein which can be specifically combined to a fat body surface in a non-covalent manner, so that precise targeting of the fat body is realized. The fat body targeting peptide segment can be widely used in the fields of precise drug delivery and vaccine preparation, so as to be used for treating diseases such as cancer, infectious diseases and metabolic diseases. Lung tissues and breast cancer cells are taken as target points, and good targeting of the fat body is realized.

Provided is a method for improving the stability of urate oxidase. The inventors have discovered that combining an active ingredient urate oxidase or chemically modified urate oxidase with a stabilizer xanthine through a non-covalent bond can significantly improve the in vivo and in vitro stability of urate oxidase and chemically modified urate oxidase in the form of a tetramer, thereby effectively improving the stability of urate oxidase.

The invention belongs to the technical field of semiconductor materials and devices, and discloses a photoelectric functional material for an organic transistor and a preparation method and application of the photoelectric functional material. A C-H activation strategy is adopted, two kinds of novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized, and the novel organic conjugated small molecules p-Ph2FTT and o-Ph2FTT containing F.H non-covalent bond conformation locks are synthesized. The molecule has excellent planarity, wide forbidden band (2.8 eV) and low HOMO energy level.

The application provides a mass spectrometry detection device and method for active protein-small molecule interaction, which uses a mass spectrometry sensor to obtain tandem mass spectrometry data of non-covalent complexes of active protein incubated with small molecule compounds at different concentration points; performs non-linear curve fitting on the concentration sequence of the small molecule compounds based on the ion combination rate of the protein binding small molecules at each concentration point, to obtain an apparent dissociation constant of the active protein-small molecule interaction; determines a local conformation change parameter of the active protein induced by small molecule binding and a potential binding domain of the small molecule; and performs fusion evaluation on the binding strength and conformation influence degree of the protein-small molecule interaction based on the apparent dissociation constant, the local conformation change parameter and the potential binding domain, to output a stability grade of the protein-small molecule interaction. Based on the above scheme, non-denatured state mass spectrometry detection of protein-small molecule complexes in a liquid phase environment can be realized.

This invention provides a Panax notoginseng-Paris polyphylla supramolecular complex, its preparation method, cosmetic products, and applications. The Panax notoginseng-Paris polyphylla supramolecular complex is a complex formed by non-covalent bonding of Panax notoginseng extract (as the host molecule) and Paris polyphylla extract (as the guest molecule), with the host molecule encapsulating the guest molecule structure. The Panax notoginseng-Paris polyphylla supramolecular complex of this invention not only improves the water solubility of Paris polyphylla extract but also increases its skin permeability and reduces its cytotoxicity. The preparation method of this invention utilizes the synergistic effect of the active ingredients, resulting in strong compatibility and synergistic efficacy. It also slows down the release time of the active ingredients, extends their shelf life, and features a simple and easy-to-control process, stable granulation effect, and low production cost.

This invention discloses a layer-by-layer deposition modified ultrafiltration membrane with both antifouling and antibacterial properties, its preparation method, and its applications. Through layer-by-layer assembly technology, a tannic acid (TA) anion layer and a polyhexamethylene biguanide (PHMB) cation layer are alternately deposited on the surface of an ultrafiltration membrane. Under weakly alkaline conditions, electrostatic interactions, hydrogen bonding, Schiff base reactions, and Michael addition reactions are simultaneously utilized to achieve both non-covalent and covalent bonding, constructing a stable and dense integrated antibacterial-antifouling composite coating. This coating has a contact-type antibacterial structure, which can effectively kill bacteria in water and inhibit biofilm formation at the source. Simultaneously, it significantly improves the hydrophilicity of the membrane surface, reduces pollutant adsorption and deposition, and achieves synergistic enhancement of antibacterial and antifouling properties. The preparation process of this invention is mild, simple, low-cost, and environmentally friendly. The modified membrane exhibits high flux retention, excellent separation performance, and excellent operational stability, and can be widely applied in water treatment scenarios such as municipal wastewater treatment.

The invention relates to the technical field of radiopharmaceuticals, and discloses a targeted GPC3 polypeptide ligand, which has a structural general formula: C-L-P, wherein C is a chelating group; l is a linker; p is a targeted phosphatidylinositol proteoglycan-3 (GPC3) polypeptide pharmacodynamic group; the linker is a covalent linker or a reversible non-covalent linker. The invention has the following technical effects: by introducing the covalent linker or the reversible non-covalent linker, the chemical structure of the targeted GPC3 polypeptide ligand is optimized, the targeting property of the targeted GPC3 polypeptide radiopharmaceutical is improved, and the pharmacokinetic characteristics are improved; the defects that an existing targeted GPC3 polypeptide radiopharmaceutical is low in tumor uptake, short in tumor residence time, poor in pharmacokinetic characteristic and the like are overcome. The invention further discloses a targeted GPC3 polypeptide radiopharmaceutical as well as a preparation method and application of the targeted GPC3 polypeptide radiopharmaceutical.

The invention discloses a natural polymer polyelectrolyte microsphere as well as a preparation method and application thereof, the microsphere is of a covalent and non-covalent double-crosslinking network structure formed by crosslinking natural polymer and polyelectrolyte, and the modification degree of the crosslinked natural polymer is 1.0-50.0%; the natural polymer is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups; and the polyelectrolyte is a compound containing more than two carboxyl groups or amino groups or a combination of the carboxyl groups and the amino groups. The preparation method comprises the following steps: S1, dissolving a natural polymer and a polyelectrolyte in a water phase to generate an electrostatic complex; s2, adding enzyme into the electrostatic complex and incubating to form microspheres; and S3, adding a condensing agent and / or a cross-linking agent, removing the unreacted condensing agent and / or cross-linking agent, and sterilizing to obtain the natural polymer polyelectrolyte microspheres. The microsphere can be used as an embolism agent in an interventional technology or a separation and purification medium of protein, antibodies and drugs or a cell and drug carrier system, or as an implant material for orthopedics, surgery, ophthalmology and medical beauty.

The present invention provides a drug-loaded nanoparticle composition suitable for drug delivery in vivo, wherein the drug-loaded nanoparticle composition is formed in the form of a non-covalent bond and comprises an active ingredient, cyclodextrin, and albumin. Drug-loaded nanoparticles or the composition thereof in the present invention are stable in a solution state, avoiding cumbersome operations of reconstitution and redissolution. Compared with a known freeze-dried powder of nanoparticles containing albumin, the nanoparticles in the present invention have a particle size of less than 150 nm, can remain stable for at least 7 days or more without change, and can be predicted to be stable for a long time.

An amphiphilic drug carrier and the use thereof in the ocular delivery of a biomacromolecular drug. The amphiphilic drug carrier is capable of penetrating the ocular mucus barrier, loading a biomacromolecular drug by means of non-covalent interaction, and delivering the biomacromolecular drug for the treatment of fundus diseases.

A nanoparticle complex comprises a bifunctional conjugate capable of non-covalently binding to lipid nanoparticles in the nanoparticle complex.

The invention belongs to the technical field of biomedical materials and tissue engineering, and particularly relates to hydrogel for treating ulcerative colitis and a preparation method thereof. The hydrogel is prepared from four functional components including oxidized dextran, chitosan, L-arginine and trithiohydracrylic acid through synergistic crosslinking, wherein the four functional components include the oxidized dextran, the chitosan, the L-arginine and the trithiohydracrylic acid; an aldehyde group of the oxidized dextran and an amino group of the chitosan are subjected to a Schiff base reaction to form a dynamic covalent cross-linked network, and a basic skeleton of the hydrogel is formed; l-arginine and guanidyl are integrated into the dynamic covalent cross-linked network through amino of the L-arginine, and trimercaptopropionic acid and carboxyl of the trimercaptopropionic acid are integrated into the dynamic covalent cross-linked network through a covalent bond or a non-covalent effect through sulfydryl of the trimercaptopropionic acid, so that a multi-site synergistic cross-linked structure is formed. The invention can solve the technical problems of single function, weak targeting property, insufficient oxidation resistance, short mucous membrane residence time, side effect risk caused by loading of exogenous drugs, limited curative effect, drug resistance and the like of the traditional treatment material.

The presently disclosed subject matter generally relates to polymer networks having covalent crosslinks, non-covalent crosslinks, and ionic side groups, and methods of making and using same. Specifically, the disclosed polymer networks can be incorporated into membranes, which can be useful in, for example, electrodialysis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

The invention relates to a supramolecular polypeptide coupled drug as well as a preparation method and application thereof. The supramolecular polypeptide coupled drug comprises a conjugate and an anti-tumor functional unit, wherein the conjugate is formed by sequentially connecting tumor targeting peptide, an enzyme response connexon and cucurbit [7] uril, and the anti-tumor functional unit is loaded onto the cucurbit [7] uril through non-covalent host-guest interaction. In the supramolecular polypeptide coupled drug, an anti-tumor functional unit is loaded on cucurbit [7] uril through non-covalent host-guest interaction, chemical modification of small-molecular drugs in a traditional method is avoided, and cucurbit [7] uril as a carrier can be compatible with various small-molecular hydrophobic drugs; due to the introduction of the tumor targeting peptide, the efficient enrichment of the medicine in tumor tissues can be realized; the unique design of the enzyme response connexon can realize rapid and efficient release of the anti-tumor functional unit in tumor cells.

This invention belongs to the field of analytical chemistry and discloses a method for analyzing non-covalent nucleic acid intercalating agents in complex mixed solutions. The method includes the following steps: (a) preparing the complex mixed solution to be tested; (b) constructing double-stranded nucleic acid molecules; (c) mechanically stretching the double-stranded nucleic acid molecules and measuring their length; (d) applying the complex mixed solution to be tested to the double-stranded nucleic acid molecules, and detecting the length change of the double-stranded nucleic acid molecules by mechanical stretching. Based on the length change, it can be determined whether a non-covalently intercalated nucleic acid-binding compound exists in the complex mixed solution. This invention is the first to use single-molecule manipulation technology to detect complex mixed solutions and identify small molecule compounds with non-covalently intercalated double-stranded nucleic acids. This method is particularly useful for screening the bioactivity of microbial nucleic acid-binding compounds, enabling the discovery of new nucleic acid intercalating compounds from microorganisms, animals, and plants.

This invention discloses an EGCG supramolecular compound with antioxidant, liver-protective, and fat-reducing effects, its preparation method, and composition. The supramolecular compound is formed by non-covalent bonding between epigallocatechin gallate (EGCG) and ligand molecules containing trimethylamine and carboxyl groups; the supramolecular compound has a co-amorphous structure; the ligand molecules containing trimethylamine and carboxyl groups are betaine, ergothioneine, or L-carnitine. This invention can solve the problems of low stability and bioavailability of EGCG. It can significantly improve the solubility of EGCG and its ligands, including betaine, L-carnitine, and ergothioneine, reduce the hygroscopicity of EGCG and its ligands, including betaine, L-carnitine, and ergothioneine, and enhance the stability and bioavailability of EGCG and its ligands, including betaine, L-carnitine, and ergothioneine.

A photoacid generator compound comprising an anion and an iodonium or sulfonium cation, wherein the anion is represented by Formula (1): (1) wherein, in Formula (1), ring Cy1 is a C3-15 monoalicyclic group or a C6-15 polyalicyclic group,; each L1 is independently a single bond or one or more linking groups, wherein L1 is free of fluorine; each X1 is independently -O-, -S-, -N(R2)-, -C(O)-, -S(O)R2-, or -S(O2)R2-, wherein R2 is independently chosen from substituted or unsubstituted C1-20 alkyl, substituted or unsubstituted C1-20 heteroalkyl, substituted or unsubstituted C6-30 aryl, or substituted or unsubstituted C3-30 heteroaryl; each Z1 independently comprises an anion stabilizing group, wherein at least one Z1 is configured to form an intramolecular non-covalent bond with the sulfonate anion group to form a ring having from 5 to 8 ring atoms, wherein the remaining substituents are as provided herein.

The invention relates to a method for regulating and controlling perovskite crystallization based on molecules with a synergistic effect, a perovskite thin film and a battery module. The method comprises the following steps: adding the molecules with the synergistic effect into a precursor solution of metal halide lead iodide; according to the preparation method, covalent coordinate bonds between synergistic molecules and metal halide lead iodide and dual-mode interaction of non-covalent pi-Pb < 2 + > are utilized, and nucleation and crystal growth processes are regulated and controlled at the same time, so that the two continuous stages of nucleation and crystal growth are regulated and controlled in the crystallization process of perovskite, and the crystallization efficiency of perovskite is improved. And slow crystal growth can be accompanied after rapid nucleation, so that the large-size perovskite homogeneous film with high crystallinity, high uniformity and low defect state density can be obtained.

The invention relates to a self-repairing flexible electronic material based on a non-covalent bond network and a preparation method and application thereof, and the preparation method comprises the following steps: mixing an organic silicon elastomer of a metal coordination bond, a functionalized carbon nanotube, zinc oxide and a peroxide vulcanizing agent, and carrying out a reaction to obtain the self-repairing flexible electronic material, the preparation method of the organosilicone elastomer with the metal coordination bonds comprises the following steps: firstly, mixing polysilicone rubber, thiohydracrylic acid and a photoinitiator, carrying out an ultraviolet irradiation reaction, then mixing a prepolymer, a coordination agent and a metal ion solution, and carrying out a reaction, so as to obtain the organosilicone elastomer with the metal coordination bonds, the preparation method of the functionalized carbon nanotube comprises the following steps: mixing the carbon nanotube and a silane coupling agent, and reacting to obtain the functionalized carbon nanotube. Compared with the prior art, the elastomer material disclosed by the invention can be widely applied to the fields of electronic skin, flexible sensors, intelligent wearable equipment and the like, and is particularly suitable for application scenes needing long-term reliability and environmental adaptability.

This application relates to the field of materials technology, specifically to a composite material, its preparation method, and its application. The composite material comprises organic molecules containing a conjugated structure and carbon materials containing π bonds, with the organic molecules loaded onto the surface of the carbon materials via non-covalent bonds. The carbon atoms in the composite material have four valence electrons, three of which are sp electrons. 2 One unbonded electron forms a π bond with a neighboring atom in a perpendicular direction. The π bond is in a half-filled state, which allows the π bond of the carbon material to interact with organic molecules with conjugated structures to form non-covalent C-H···π bonds. This enables organic molecules to be loaded onto the surface of the carbon material, greatly improving the catalytic activity of the composite material. It also gives the composite material good anti-agglomeration and stability, and makes the composite material easy to recycle after use.

This invention discloses a medical repair hydrogel and its preparation method, specifically relating to the field of biomedical engineering technology. The hydrogel is a three-dimensional network structure formed by the synergistic self-assembly of glycyrrhizic acid and polydipsia glycoside through non-covalent bonds such as hydrogen bonding, hydrophobic interactions, and π-π stacking. No chemical cross-linking agent is required. It spontaneously forms a hydrogel upon heating to 70°C until completely dissolved and then cooling. It possesses reactive oxygen species-responsive structural dissociation characteristics, mechanical properties adapted to myocardial tissue, and a controllable degradation rate. This invention is suitable for intramyocardial drug administration after PCI, avoiding the shortcomings of traditional synthetic hydrogels that require external triggering and have unsuitable gelation conditions. Simultaneously, its three-dimensional network structure enables simultaneous long-term sustained release of the two active ingredients, with a 24-hour burst release rate of less than 25% and a cumulative release rate exceeding 70% within 7 days. This solves the problem of short half-lives and rapid clearance by body fluids of small molecule drugs, achieving continuous drug delivery to the lesion site.

Provided is a nanoparticle including a scaffold, a single template site for bonding a template polynucleotide to the scaffold, and a plurality of accessory sites for bonding accessory oligonucleotides to the scaffold, wherein the scaffold is selected from an asymmetrical acrylamide polymer one or a dendrimer including lysyl constitutional repeating units, the single template site for bonding a template polynucleotide to the scaffold is selected from a covalent template bonding site and a noncovalent template bonding site and the plurality of accessory sites for bonding accessory oligonucleotides to the scaffold are selected from covalent accessory oligonucleotide bonding sites and noncovalent accessory oligonucleotide bonding sites. Also provided are methods of using the nanoparticle.

The application discloses a nano-drug delivery system containing a stabilizer and a preparation method and application thereof, and belongs to the technical field of medicine preparation. The nano-drug delivery system containing the stabilizer comprises a cationic polypeptide / siRNA complex and a particle size stabilizer; the cationic polypeptide / siRNA complex is formed by non-covalent force between a cationic polypeptide and siRNA, and the amino acid sequence of the cationic polypeptide is KKK(RH4RH4RH4RH4R) x wherein x=3 or 4; and the particle size stabilizer is a surfactant or a protein. Experiments prove that the delivery system combined with the cationic polypeptide and the particle size stabilizer has stable nano size in pure water and biological matrix, and has high gene silencing efficiency at the cell level, and does not significantly reduce the cell transfection or knockout efficiency. Therefore, the nano-drug delivery system can keep nano size in the biological matrix for a long time, and has particle size stability.

The present disclosure discloses a target cell-targeting complex and use thereof. The complex comprises (1) a first molecule: a protein comprising an Fc fragment, and (2) a second molecule: a fragment comprising an enzyme and capable of being linked to the first molecule non-covalently to form a stable structure, and the complex retains the activity of each part. After being administered to a subject, the targeting complex can fulfill the function of targeting proteins and enzymes.

This invention discloses a butyrate prodrug co-assembled with artesunate, its preparation method, and its application in kidney diseases, belonging to the field of biomedical technology. The invention first uses docosahexaenoic acid (DHA) as a hydrophobic framework, coupling it with 2,2'-dithiodiethanol to introduce disulfide bonds, and then grafts butyrate via esterification to obtain a butyrate prodrug. The butyrate prodrug and artesunate self-assemble through non-covalent interactions to obtain a co-assembled drug in nanoparticle form. This nanomedicine possesses excellent long-term in vivo circulation and passive targeted accumulation in the kidneys, and can achieve targeted drug release in response to the high-glutathione microenvironment within lesion cells. The two active ingredients synergistically exert metabolic regulation, anti-inflammatory, and antioxidant effects, inhibiting kidney inflammation and oxidative stress at multiple targets, protecting renal tubular epithelial cells, and effectively intervening in the pathological process of acute kidney injury. Furthermore, this drug has high biosafety, is simple to prepare, and is easy to scale up, showing broad application prospects in the prevention and treatment of kidney diseases.

The invention discloses a signal-drift-free and low-lag ionization type capacitance pressure sensor and a preparation method and application thereof. The ionization type capacitance pressure sensor comprises a capacitance medium and substrates which are attached to the upper surface and the lower surface of the capacitance medium and comprise electrodes. The capacitor medium takes silicone rubber foam as a matrix, the surface of the silicone rubber foam is uniformly coated with a layer of polydopamine, the polydopamine is combined on the surface of the silicone rubber foam through multi-covalent and non-covalent interaction, and a bis (fluorosulfonyl) imide ion layer is formed on the surface of the polydopamine through protonation and ion exchange. The ionizing capacitive pressure sensor provided by the invention shows excellent detection performance in a wider pressure range, is high in sensitivity, high in response speed, good in long-term stability, capable of working in a wider temperature range and good in high and low temperature resistance stability, and the stability is remarkably superior to that of a traditional ion electronic sensor; and a solid foundation is laid for the development of real-time physiological signal monitoring and intelligent man-machine interaction systems.

A method for extracting at least 55% of immunoglobulin such as IgG from a biological fluid. The biological fluid containing immunoglobulin is contacted with a solid support covalently bonded to a ligand that specifically binds to immunoglobulin under conditions sufficient for non-covalent binding of immunoglobulin to the ligand. The solid support is contacted with an elution solution under conditions whereby the non-covalently bound immunoglobulin is released from the ligand and into the elution solution, wherein at least 55% of the IgG present in the biological fluid is extracted into the elution solution. The method, in some embodiments, provides a method for enriching immunoglobulin from a biological fluid comprising obtaining an initial biological fluid suspected of containing immunoglobulin and removing non-immunoglobulin components naturally occurring in the initial biological fluid to obtain a non-immunoglobulin component-reduced biological fluid.